 "pharmaceutical, pharma, testing, research, doctors, health, drugs, medicine, labaratory")
US major Gilead's remdesivir, which has shown potential to reduce the viral load in Covid-19 patients, is likely to be priced lower than the global rate in India, according to multiple sources close to the development. The Indian pricing regulator is keeping a close watch on the situation, and would review the prices once companies launch the product in Indian market.
Meanwhile, several traders have quoted prices (for example Rs 15,000 for 100 mg/20 ml vials) for remdesivir on online business-to-business shopping sites even before the drug is available in the market. Indian companies clarify that this is far from the
